ideasIdea
CD30 CAR-T for multiply relapsed Hodgkin lymphoma
Engineer T cells against CD30 for the few patients who fail brentuximab, PD-1 blockade and transplant.
Phase 1/2 CD30 CAR-T (UNC/Baylor; Tessa Therapeutics TT11) produced ORR ~62-72% and CR ~50-60% with fludarabine-based lymphodepletion; durability modest. A pivotal CHARIOT study was halted for business reasons in 2023-24.
Hypothesis
CD30 CAR-T after PD-1 failure yields durable CR in ≥40% of patients with an acceptable CRS profile, and combination with PD-1 blockade prolongs persistence.
Rationale
CD30 is near-universal on Reed-Sternberg cells and shed CD30 does not block binding at therapeutic doses; the inflamed microenvironment supports CAR-T trafficking.
What would test it
Randomised phase 2 of CD30 CAR-T ± nivolumab vs investigator's choice in triple-refractory disease.
Maturity
early clinical
Pages like this
not linked directly; found by shared links- TermReed-Sternberg cell
Shares CD30, Hodgkin lymphoma.
- TrialECHELON-1
Shares CD30, Hodgkin lymphoma.
- InstitutionJuravinski Cancer Centre / Escarpment Cancer Research Institute
Shares Hodgkin lymphoma, CAR-T cell therapy.
- InstitutionDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Shares Hodgkin lymphoma, CAR-T cell therapy.
- InstitutionUniversity Hospitals Birmingham / University of Birmingham Cancer Research Centre
Shares Hodgkin lymphoma, CAR-T cell therapy.
- Key paperECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma
Shares CD30, Hodgkin lymphoma.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'Orsola
Shares Hodgkin lymphoma, CAR-T cell therapy.
- Key paperSWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults
Shares CD30, Hodgkin lymphoma.